Laboratorios Grifols: our origins

Dr. Josep Antoni Grífols i Roig and his sons establish Laboratorios Grifols in Barcelona, dedicated to clinical analysis, the manufacture of vaccines and blood transfusions.


The first lyophilized plasma in Europe

Grifols patents this process in Spain and develops a lyophilizer plus complementary devices in order to use plasma subsequently for therapeutic purposes.


The blood bank is born

Grifols opens the first private blood and plasma bank in Spain.


Plasmapheresis: a new way to collect plasma

Dr. Josep Antoni Grífols i Lucas develops this innovative technique, which allows reintroducing the donor's red blood cells immediately after extraction.


The first steps in fractionation

The first plasma fractionation plant in Spain begins operations.


A notable increase in production

Grifols opens a new production plant in Barcelona.


Very high standards of quality

With its production plant in Barcelona, Grifols becomes the first Spanish company to receive an FDA license for its installations and for its production of a biological product (albumin).


New plasma suppliers

Grifols acquires the US company SeraCare (currently Biomat) and its 43 donation centers.


Direct presence in US

Grifols acquires the assets of Alpha Therapeutic Corporation-Mitsubishi, including its plasma fractionation plant in Los Angeles, California.


Industrial expansion

FDA approval for the immune globulin (IG) plant in Barcelona. Listing on the Spanish stock exchange IBEX35.


A boom in the plasma industry

Grifols acquires Talecris Biotherapeutics to become the third largest manufacturer of plasma-derived medicines in the world. Listing on the NASDAQ exchange.


The Diagnostic Division grows

Acquisition of the Novartis diagnostics business unit.


Global leaders in transfusion medicine

Grifols acquires Hologic's NAT donor screening unit.


Business consolidation

Grifols becomes the worldwide leader in plasma donation centers, with 190 centers in the US.